2017年最新期刊SCI影响因子数据已经更新，欢迎查阅！
 |
| 基本信息 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 期刊名字 | MOLECULAR CANCER THERAPEUTICS MOL CANCER THER1. 期刊Molecular Cancer Therapeutics推荐LetPub编辑服务 | ||||||||
| 期刊ISSN | 1535-7163 | ||||||||
| 2016-2017最新影响因子 | 5.764 | ||||||||
| 2016-2017自引率 | 2.60% | ||||||||
| 期刊官方网站 | http://mct.aacrjournals.org/ | ||||||||
| 期刊投稿网址 | http://mct.msubmit.net/cgi-bin/main.plex | ||||||||
| 是否OA开放访问 | No | ||||||||
| 通讯方式 | AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404 | ||||||||
| 涉及的研究方向 | 医学-肿瘤学 | ||||||||
| 出版国家或地区 | UNITED STATES | ||||||||
| 出版周期 | Monthly | ||||||||
| 出版年份 | 2001 | ||||||||
| 年文章数 | 287 | ||||||||
| 中科院SCI期刊分区 （ 2016最新版本） |
| ||||||||
| SCI期刊coverage | Science Citation Index Expanded | ||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1535-7163%5BISSN%5D | ||||||||
| 平均审稿速度（网友分享经验） | 平均3月 | ||||||||
| 平均录用比例（网友分享经验） | 约50% | ||||||||
| 期刊常用信息链接 |
|
| |
| 中国学者近期发表的论文 | |
| 1. | Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer. Author: Feng J, Zhang S, Wu K, Wang B, Wong JY, Jiang H, Xu R, Ying L, Huang H, Zheng X, Chen X, Ma S. Journal: Mol Cancer Ther. 2016 May;15(5):842-53. doi: 10.1158/1535-7163.MCT-15-0445. Epub 2016 Feb 2. |
| 2. | Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption. Author: Xu L, Luo J, Jin R, Yue Z, Sun P, Yang Z, Yang X, Wan W, Zhang J, Li S, Liu M, Xiao J. Journal: Mol Cancer Ther. 2016 May;15(5):854-65. doi: 10.1158/1535-7163.MCT-15-0669. Epub 2016 Feb 9. |
| 3. | Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53. Author: Karan G, Wang H, Chakrabarti A, Karan S, Liu Z, Xia Z, Gundluru M, Moreton S, Saunthararajah Y, Jackson MW, Agarwal MK, Wald DN. Journal: Mol Cancer Ther. 2016 Apr;15(4):574-82. doi: 10.1158/1535-7163.MCT-15-0467. Epub 2016 Feb 16. |
| 4. | Long Noncoding RNA PVT1 Promotes Non-Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression. Author: Wan L, Sun M, Liu GJ, Wei CC, Zhang EB, Kong R, Xu TP, Huang MD, Wang ZX. Journal: Mol Cancer Ther. 2016 May;15(5):1082-94. doi: 10.1158/1535-7163.MCT-15-0707. Epub 2016 Feb 23. |
| 5. | Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis. Author: Yang J, Qian S, Cai X, Lu W, Hu C, Sun X, Yang Y, Yu Q, Gao SP, Cao P. Journal: Mol Cancer Ther. 2016 Jun;15(6):1190-200. doi: 10.1158/1535-7163.MCT-15-0551. Epub 2016 Feb 29. |
| 6. | Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma. Author: Gifford JB, Huang W, Zeleniak AE, Hindoyan A, Wu H, Donahue TR, Hill R. Journal: Mol Cancer Ther. 2016 May;15(5):1043-52. doi: 10.1158/1535-7163.MCT-15-0774. Epub 2016 Mar 3. |
| 7. | BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer. Author: Wu X, Liu D, Tao D, Xiang W, Xiao X, Wang M, Wang L, Luo G, Li Y, Zeng F, Jiang G. Journal: Mol Cancer Ther. 2016 May;15(5):1029-42. doi: 10.1158/1535-7163.MCT-15-0750. Epub 2016 Mar 3. |
| 8. | Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression. Author: Shi L, Lin H, Li G, Jin RA, Xu J, Sun Y, Ma WL, Yeh S, Cai X, Chang C. Journal: Mol Cancer Ther. 2016 Apr;15(4):731-42. doi: 10.1158/1535-7163.MCT-15-0706. Epub 2016 Mar 3. |
| 9. | RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. Author: Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P. Journal: Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1. |
| 10. | Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma. Author: Du Z, Caenepeel S, Shen Y, Rex K, Zhang Y, He Y, Tang ET, Wang O, Zhong W, Zhou H, Huang J, Huang E, Hu L, Coxon A, Zhang M. Journal: Mol Cancer Ther. 2016 Jun;15(6):1227-37. doi: 10.1158/1535-7163.MCT-15-0745. Epub 2016 Mar 29. |
|
|
| 首页 上一页 1 下一页 尾页 (去 | |
同领域作者分享投稿经验： |
我来分享 |
| 分享者 | 点评内容 |
| 第1楼 作者：SCI 发表日期： 2015-01-11 10:25:39  (顶3)  (踩0) 我来分享 | 研究方向：医药科学 肿瘤学 血液淋巴肿瘤（白血病除外） 投稿周期：1.0 个月 录用情况：已投修改后录用 |
| 首页 上一页 1 下一页 尾页 (去 | |
安全保密
